Business Context and Reporting Period
Company: CorMedix Inc. (CRMD)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: CorMedix is a biopharmaceutical company focused on therapeutic products for life-threatening diseases. Following the acquisition of Melinta Therapeutics in August 2025, the company now commercializes its flagship product, DefenCath, alongside the Melinta portfolio (including REZZAYO, MINOCIN, VABOMERE, KIMYRSA, ORBACTIV, BAXDELA, and TOPROL-XL). The financial results for the current period include the Melinta portfolio, whereas the prior year period (2025) did not.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended June 30, 2026 |
6 Months Ended June 30, 2026 |
6 Months Ended June 30, 2025 |
|---|---|---|---|
| Total Revenue & Grant Income | $101,931 | $229,358 | $78,818 |
| Net Income | $25,988 | $64,589 | $40,472 |
| Diluted EPS | $0.29 | $0.72 | $0.58 |
| Operating Cash Flow (6mo) | N/A | $128,619 | $49,728 |
| Cash & Equivalents (Balance Sheet) | $256,692 | $256,692 | $144,837 |
| Convertible Senior Notes (Net) | $145,150 | $145,150 | $144,626 |
| Contingent Consideration Liability | $111,619 | $111,619 | $102,116 |
Margins (6 Months 2026): Gross Profit margin was approximately 79.5% ($182.2M / $229.4M). Operating margin was approximately 46.5% ($106.6M / $229.4M).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 191% year-over-year for the six months ended June 30, 2026, driven by the inclusion of the Melinta portfolio and continued growth in DefenCath sales.
- Profitability: Net income increased 60% year-over-year. The effective tax rate rose significantly to 31.6% (from 1.3% in the prior year) as the company no longer maintained a full valuation allowance against federal deferred tax assets.
- Operating Expenses: Total operating expenses increased 112% year-over-year, primarily due to the integration of Melinta, increased personnel costs, and higher amortization of intangible assets ($20.6M vs $0.1M in the prior year).
- Non-Operating Items: A $10.9M expense related to the change in fair value of contingent consideration was recorded for the six months ended June 30, 2026, compared to none in the prior year. This was driven by accretion and changes in discount rates.
- Accounting Estimate Changes: A change in estimate regarding Medicaid rebates and product returns positively impacted net sales by $9.0M and net income by $6.1M for the six months ended June 30, 2026.
Guidance, Outlook, and Risks
- REZZAYO Development: Positive Phase III topline results were announced in April 2026 for REZZAYO in the prophylaxis of invasive fungal diseases. Commercialization in this second indication is targeted for 2027 pending FDA approval.
- DefenCath Reimbursement: Effective July 1, 2026, DefenCath reimbursement transitioned to a post-TDAPA Add-On Adjustment. Management expects a significant decline in net pricing and sales for the second half of 2026, with a potential increase in 2027.
- Tariffs: New U.S. tariffs on imported pharmaceutical ingredients announced in April 2026 may adversely affect gross margins. The company is onshoring manufacturing to mitigate these costs.
- Legal Proceedings:
- Securities Litigation: Ongoing class action litigation regarding DefenCath NDA submissions. The company recorded $4.2M in loss recovery credits for legal fees expected to be covered by insurance.
- Derivative Litigation: A binding settlement term sheet was signed in December 2025 for the federal derivative action, with preliminary approval granted in July 2026. A separate state derivative action is stayed pending the federal outcome.
- Patent Litigation: The Federal Circuit affirmed the validity of MINOCIN patents against Nexus Pharmaceuticals in June 2026. Litigation against Gland Pharma is ongoing.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2026, due to a material weakness in the review of significant non-routine transactions. Remediation efforts are underway.
- Share Repurchases: The company repurchased 2.4 million shares for $17.5M during the first six months of 2026 under a $75M program authorized in February 2026.
Investor Verification Checklist
- Reimbursement Impact: Verify the magnitude of the expected revenue decline for DefenCath in H2 2026 due to the CMS reimbursement methodology change.
- Contingent Consideration: Monitor the fair value of the $111.6M contingent consideration liability, which is sensitive to discount rates and sales forecasts for REZZAYO and MINOCIN.
- Internal Control Remediation: Track progress on remediation of the material weakness in internal controls over financial reporting.
- Legal Settlements: Confirm final approval of the derivative litigation settlement and the status of the securities class action.
- REZZAYO Approval: Watch for FDA approval timelines for the second indication (prophylaxis) to assess the likelihood of the $20M+ milestone payment and future royalty streams.
- Tariff Mitigation: Assess the success of onshoring manufacturing initiatives in offsetting new tariff costs.